Silvia Salvans

Silvia Salvans

Auto-generated profile, based on publicly available information

Silvia Salvans

Section of Colon and Rectal Surgery, Department of Surgery, Hospital del Mar, 08003 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 June 2023 in Surgery
Verified
Journal Article
Closed access
JOJuan Ocaña
Juan Ocaña
JGJuan Carlos García-Pérez
Juan Carlos García-Pérez
DFDaniel Fernández-Martínez
Daniel Fernández-Martínez
IAIgnacio Aguirre
Ignacio Aguirre
IPIsabel Pascual
Isabel Pascual
JLJavier López-Ruiz
Javier López-Ruiz

26 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
VMVALENTINO MARTELLI
VALENTINO MARTELLI
JVJoana Vidal
Joana Vidal
SSSílvia Salvans
Sílvia Salvans
CFConcepción Fernandez-Rodriguez
Concepción Fernandez-Rodriguez
JBJordi Badia-Ramentol
Jordi Badia-Ramentol
CMClara Montagut
Clara Montagut
Peritoneal carcinomatosis (PC) represents a challenge in the management of metastatic colorectal cancer (mCRC) because of the difficulties in diagnosis, tumor burden assessment, and in selecting the optimal treatments. A critical limitation is the lack of robust prognostic and predictive biomarkers, largely relying on serum markers (e.g., carcinoembryonic antigen) or the peritoneal carcinomatosis index (PCI) for disease extent. Circulating tumor DNA (ctDNA)—genomic fragments shed by tumor cells into the bloodstream—is now recommended by international guidelines for mCRC management. Its potential extends to PC, where it may enhance diagnostic, therapeutic, and follow-up strategies. However, PC from CRC (PC-CRC) is associated with lower ctDNA levels and detection rates compared to other metastatic sites, posing a challenge for its clinical utility. To address these limitations, peritoneal fluid analysis has emerged as a promising alternative, with peritoneal tumor DNA (ptDNA) detected at higher concentrations in this anatomical space. Integrating ctDNA and ptDNA may offer a deeper understanding of PC-CRC biology and provide more precise tools for managing this complex disease. This approach has the potential to revolutionize the treatment paradigm for PC-CRC, bringing precision medicine even to this subgroup of patients traditionally associated with poor outcomes. This review aims to evaluate the diagnostic, prognostic, and therapeutic implications of ctDNA and ptDNA in PC-CRC, highlighting current limitations and future directions.